EUVIMEDEUVIMED entdecken
Crossref

Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial

Alexa Dang, David A Palma, Edward Wang, Pencilla Lang, Andrew Warner, Houda Bahig, Alexander V Louie, Stephen Harrow, Meredith E Giuliani, Brock J Debenham, Christopher J Ryerson, Stewart Gaede

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.09.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Alexa Dang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada; Division of Radiation Oncology, Wes…. Hauptthemen laut MEDLINE: Lung Neoplasms, Lung Diseases, Interstitial, Radiosurgery, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AstraZeneca, Varian Medical Systems, London Health Sciences Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: SABR therapy in the setting of interstitial lung disease (ILD) is associated with higher toxicity risks. This dosimetric analysis of the ASPIRE-ILD trial evaluates doses delivered to targets and organs at risk, and correlations between baseline factors and outcomes, to better inform patient selection and treatment planning. METHODS AND MATERIALS: Radiation plans were centrally reviewed, and descriptive statistics were used to assess doses to targets and organs at risk. Unadjusted Cox proportional hazards and logistic regression were performed to identify predictors of overall survival, local control, and related adverse events. Linear regression was performed to identify significant predictors of the Functional Assessment of Cancer Therapy: Lung. RESULTS: The cohort included 39 patients with early-stage lung cancer and ILD treated with SABR (50 Gy in 5 fractions every other day). The mean internal gross tumor volume and planning target volume (PTV) were 12.0 ± 11.2 cc and 33.9 ± 22.0 cc, respectively. The mean ± SD maximum dose was 64.2 ± 6.3 Gy. On unadjusted analyses, local control decreased with increasing tumor size [measured as either internal gross tumor volume size (P = .038) or PTV size (P = .033)]. The risk of grade ≥2 adverse events increased with higher heart maximum dose (P = .020) and heart D15cc (P = .025), and with increasing fibrosis surrounding the tumor [measured as the Hounsfield unit density of lung immediately surrounding the PTV (P = .006)]. Worse overall survival was associated with ILD subtype, previous or current ILD treatment, home oxygen use, and larger target sizes. Smoking cessation and a diagnosis of idiopathic pulmonary fibrosis were associated with improved Functional Assessment of Cancer Therapy: Lung scores at 6 months. CONCLUSIONS: Several factors were associated with clinically relevant outcomes after SABR in patients with ILD, including radiation dose to the heart and smoking cessation. SABR delivered to highly fibrotic areas of the lung was associated with higher toxicity. Smoking cessation may be important in preserving quality of life after treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsLung Diseases, InterstitialRadiosurgeryCarcinoma, Non-Small-Cell LungHumansMaleFemaleAgedMiddle AgedOrgans at RiskTumor BurdenRadiotherapy DosageLungTreatment OutcomeAged, 80 and overHeartProportional Hazards Models

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada; Division of Radiation Oncology, Western University, London, Ontario, Canada. Electronic address: alexa.da…
  • Division of Radiation Oncology, Western University, London, Ontario, Canada.
  • Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
  • Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Edinburgh Cancer Centre, Edinburgh, Scotland.
  • Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Förderung

  • AstraZeneca
  • Varian Medical Systems
  • London Health Sciences Foundation
  • Ontario Institute for Cancer Research

Zitieren

APA

Dang, A., Palma, D. A., Wang, E., Lang, P., Warner, A., Bahig, H., Louie, A. V., Harrow, S., Giuliani, M. E., Debenham, B. J., Ryerson, C. J., & Gaede, S. (2025). Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.09.026

Vancouver

Dang A, Palma DA, Wang E, Lang P, Warner A, Bahig H, et al. Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.09.026

BibTeX
@article{Dang2025,
  author = {Dang, Alexa and Palma, David A and Wang, Edward and Lang, Pencilla and Warner, Andrew and Bahig, Houda and Louie, Alexander V and Harrow, Stephen and Giuliani, Meredith E and Debenham, Brock J and Ryerson, Christopher J and Gaede, Stewart},
  title = {Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.09.026}
}
Kostenlos starten →